Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
Steven C MarcusAnand R ShewaleStephen D SilbersteinRichard B LiptonWilliam B YoungHema N ViswanathanJalpa A DoshiPublished in: Cephalalgia : an international journal of headache (2020)
In a US commercial health plan, almost one-third of new triptan users were potential triptan insufficient responders and the majority filled opioid prescriptions. Potential triptan insufficient responder patients had significantly higher all-cause and migraine-related healthcare utilization and costs than triptan-only continuers.